Kaluza C Analysis Software

Kaluza C Analysis Software is built upon our successful Kaluza Analysis research use platform.

We’ve turned our attention now to the unique needs and challenges of the clinical flow cytometry laboratory. Clinical laboratories are under increasing pressure from three sources: reimbursement, regulatory, and resource. Meeting regulatory requirements places demands on both time and expertise.

Kaluza C Analysis Software provides features that streamline the clinical QC reporting requirements and address standardization issues in flow cytometry. At the same time it provides the power to processes multi-color files of up to 20 million events in real time.

Download our 30-day free trial

Features

The Kaluza Philosophy 

  • Context specific radial menus put functions at your fingertips
  • Four control panels access all aspects your data
  • Real time adjustments to data display

Clinical Reporting Features

Quality Control Features

Administrator Tools

  • Oversee setup functions and review activities for all accounts
  • Create detailed usage reports and query logs for specific users
  • View current license keys and use to activate new keys

Explore Kaluza C Models

Content and Resources

Filter by:
Resource Type
Offline Flow Cytometry Analysis Software: Importance of Scaling and Data Visualization This whitepaper discussed the flow cytometry open platform data structure and how it facilitates for robust offline analysis, the importance of data scaling and display features in ensuring your data looks consistent with the native environment, and illustrates specific examples comparing the native display to an offline data analysis software across a variety of platforms and manufacturers.
Kaluza C Analysis Software Brochure Kaluza C Analysis Software streamlines clinical QC reporting requirements and addresses flow cytometry standardization issues
Using Standardized Dry Antibody Panels for Flow Cytometry in the Assessment of Altered Immune Profiles in Response to SARS-CoV2 Infection In order to identify early indicators of disease severity in SARS-CoV2-infection, the proportions of well-established immune cell phenotypes have been subject to extensive research, utilizing flow cytometry as a core technology1-3. In order to ensure comparable and consistent results in the massively multi-institutional research setting of a global pandemic, the use of standardized antibody panels and procedures, as demonstrated by The ONE Study4-6, is a promising approach that also can lower technical barriers

Documentos técnicos